[ 3 / biz / cgl / ck / diy / fa / ic / jp / lit / sci / vr / vt ] [ index / top / reports ] [ become a patron ] [ status ]
2023-11: Warosu is now out of extended maintenance.

/biz/ - Business & Finance


View post   

File: 194 KB, 382x597, 1381425483358.png [View same] [iqdb] [saucenao] [google]
58429 No.58429 [Reply] [Original]

>Business & Finance
>posting about doge/bitcoin
>posting how can I get rich quick
>posting how can I get into gambling
>posting I have X, what's the next big stock so I can win at the stock market and never do anything again
>posting anything /pol/

Not even 100,000 posts and this place has gone to shit, so it's time for a real fucking deal thread.

SECURITIES ANALYSIS THREAD MOTHERFUCKERS

What strategies are you guys using, what research are you doing, what stocks are you about to take action on NOT BECAUSE THEY ARE THE NEW TREND but because you saw the MACD divert or you think its current rise/fall is about to end or earnings sucked and you saw their balance sheets. What companies have new products that you actually think are game changers, what companies are about to lose their patents? What does morningstar, S&P, rheuters, say in their latest reports. Going long, going short, hedging with options, let's fukken do it.

Fundamental, technical and quantitative analyses are all welcome.

>> No.58492

>>58429
Gilead sciences, market dominance of its HIV franchise that is extremely successful (just got fresh patent protection by combining its three pills into one). Strong pipeline specifically related to cancer drugs (most specifically idealisib had amazing p3 results). Their Hep C drug currently priced at 84k in the U.S. beat the competitors to market by a few quarters, is much more convenient. Analysts are projecting sales could hit 5-6 billion this year, and peak at 16 billion, yet prescription rates indicate it could be even higher. Not to mention that through some strange tax moves the more hep c drugs they sell the lower their tax rate.

Lots of debt that will be paid off soon, good safe healthcare pick, obongocare should also bring positive headwings. Also the Hep c competition has stated they won't try to compete on price.

>> No.58583

Ford (F) has been down a bit after some recent gains late last year. MACD has just crossed the signal line so it might be signalling a small jump up. They've been selling their main couple of cars as well as GM according to some of the analysts and they've fixed up some of their cheaper cars to compete with toyota, nissan and the like. Q4 2013 had better than expected earnings.

It's a cyclic industry but also production can be affected by any changes regarding unions. But I think I might want to buy a few more shares before it hits 17.00

Any input?

>> No.58672

>>58492
They also own tamiflu, let someone else market it and collect large royalties, no major patent expiration for many years, and plenty of other things in the pipeline.

>>58583
NOt really sure how I feel about Ford I just don't really see any potential for them to really change the status quo. I stay away from industries like that. If you want exposure to that market you should look at someone like borgwarner. they basically seld turbochargers and other car parts to EVERYONE in the industry, and as fuel efficiency becomes increasingly important their products will be in higher demand. It's almost like purchasing an "auto industry etf".

I really like the idea of this thread but I have to go please don't let it die, we need more of this instead of shitty hurr durr whatever coin threads.

>> No.58780

>>58672
>>58492
I like Gileads foray into viral treatments. I have Pfizer right now, they've been doing pretty well and should continue doing so because of what barron's calls their "underappreciated" pipeline.

They also have an all-star product lineup:
Viagra, Zoloft, Xanax, Chantix, Advil, Lipitor (even though the patent died). They've got a good amount of pressure from offbrand meds but they seem to be a pretty good long term safe bet with their dividend.

International Paper (IP) seems to have some projected growth (1%) and that they may increase their sales by potentially up to 5% this year. A good bit of their focus seems to be in packaging type paper goods right now. They are facing issues with companies in developed countries going paperless for a lot of things though

>> No.58807

FSYS: tell me that's not a bottom.

DDD: about to cross 50 SMA on the daily

>> No.58843

>>58780
I'd avoid IP... paperless is bad for a paper company.

>> No.58992

>>58843
Paperless is hurting them but they just acquired Temple-somethingoranother which supposedly puts them at the forefront of packaging materials. There's no amount of paperless people do right now where they ship objects paperlessly.

FSYS: It's come up a bit from it's new 52week low at the beginning of the month, I wish I had bought it then

DDD: 12:44 pm 3D Systems and Hasbro (HAS) announced partnership to co-develop, co-venture and deliver play experiences powered by 3D printing (DDD) from yahoo finance

They jumped up ion the market pretty quick too, but it's tough to get on board with how volatile it seems and with no two analysts able to agree on whether they want to buy or sell them.

>> No.59018

>>58429
You're a dumb fag.

>> No.59384

>>58429
Why would I tell you ?

>> No.60232

CRY

Volume spike
macd reversal
stochastic divergance
bounce off the lower bollinger last week, higher close everyday after

closed at 10.19 friday, looks like it could hit/break 11 this week.

>> No.60695

>>58780
I had Pfizer, sold it for gilead and saw significant price appreciation while pfizer hasn't done much. I'm not a big fan of their pipeline though so maybe I'm one of those people that doesn't appreciate it.


Also BUMP